Daridorexant scores in the first of two phase III insomnia studies, but attention will fall on a secondary endpoint measuring daytime performance.
Novo Nordisk has high hopes that obesity will become a major source of sales, and data on the company’s most promising projects are looming.
A negative reaction to positive migraine data sends Biohaven down.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
Six months after evobrutinib’s two pivotal multiple sclerosis studies started enrolment, their comparator cohorts are overhauled.
Medtronic has lined up a whole pipeline of new devices – and it will need them.